{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Returned from each subject', 'Disposed of at the clinical site or returned to the Sponsor or designee', 'The clinical monitor responsible for the clinical site will provide written approval for the', 'destruction or return of used and unused elamipretide delivery system supplies following', 'reconciliation of all clinical supplies.', '8.4.', 'Treatment Compliance', 'During the treatment period, IMP will be administered with the elamipretide delivery system', 'daily by a trained caregiver, or self-administration. A diary will be used to document', 'administration.', '8.5.', 'Randomization', 'The randomization for PART 1 will be based on a 1:1 ratio of elamipretide to matching placebo.', 'The randomization will be centrally administered through an IWRS. Subjects will be stratified by', \"the subclassification of the mutation determined to be the primary cause of the subject's PMM\", '(DiMauro 2003) as determined by the Adjudication Committee:', 'Disorders involving mtDNA mutations that impair mitochondrial protein synthesis in', 'toto', 'Disorders involving mtDNA mutations that affect the subunits of the respiratory', 'chain', 'Disorders involving nDNA mutations in genes encoding subunits or ancillary proteins', 'of the respiratory chain', 'Disorders involving nDNA mutations causing defects of intergenomic signaling', 'Disorders involving nDNA mutations causing defects of mitochondrial protein', 'importation', 'Disorders involving nDNA mutations causing alterations of the lipid milieu of the', 'inner mitochondrial membrane', 'Disorders involving nDNA mutations causing alterations of mitochondrial motility or', 'fission', 'There is no randomization for PART 2.', '8.6.', 'Blinding and Unblinding Procedures', 'Trial personnel and subjects will be blinded to treatment in PART 1 until the PART 1 database is', 'locked.', \"The Investigator will contact the Sponsor prior to unblinding any subject's treatment sequence\", 'unless in the instance of a medical emergency.', 'In case of an immediate medical emergency or if directed by the Sponsor, and only if the', \"information is required by the Investigator to manage a subject's AE, is a subject's treatment\", 'assignment to be unblinded prematurely. In cases of medical emergency, the Investigator may', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '60']['SPIMM-301 Version 4.0', '15 June 2018', \"unblind a subject's treatment assignment using the computerized system according to the\", 'instructions received. The Sponsor must be notified as soon as possible regarding the reason for', 'unblinding.', 'Whenever the treatment assignment of an individual subject is unblinded, the individual who', 'performed the unblinding, the date, time and reason for the unblinding must be logged in the', 'computerized unblinding system (IWRS) and also included in source documentation. The name', \"of the individual who broke the blind must be included in the clinic's source documentation.\", 'The Sponsor designated CRO will control and document, according to the appropriate Standard', 'Operating Procedures, the disclosure of treatment assignments, and treatment identity. These', 'procedures ensure that no blinded staff (CRO, clinical site staff, Sponsor) will have premature', \"access to the subjects' treatment assignments.\", 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '61']['SPIMM-301 Version 4.0', '15 June 2018', '9.', 'EFFICACY AND SAFETY EVALUATIONS AND', 'APPROPRIATENESS OF MEASUREMENTS', '9.1.', 'Efficacy Enppoints', 'Efficacy will only be assessed for PART 1.', '9.1.1.', 'Primary Enppoints', 'The primary endpoints are:', 'Distance walked (meters) during the 6MWT', 'Total Fatigue score on the PMMSA', '9.1.2.', 'Secondary Enppoints', 'The secondary endpoints are:', 'Fatigue During Activities score on the PMMSA', 'Neuro-QoL Fatigue Short Form score', 'Most bothersome symptom score on the PMMSA', 'Neuro-QoL Fatigue activities of daily living (specific items from the Neuro-QoL Item', 'Bank)', '9.1.3.', 'Exploratory Enppoints', 'There will be a number of exploratory endpoints investigated, including:', 'Individual symptom scores on the PMMSA', 'Alternate version of the PMMSA Total Fatigue Score', 'Individual item scores of the Neuro-QoL Fatigue', 'EQ-5D-5L scores', 'Patient Global Impression (PGI) Scales', '- PGI of Symptom scores', '- PGI of Change scores', 'Clinician Global Impression (CGI) Scales', '-', 'CGI of Symptom scores', '- CGI of Change scores', '9.1.4.', 'Pharmacokinetic (PK) Enppoints', 'The PK endpoints are:', 'PK parameters', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '62']\n\n###\n\n", "completion": "END"}